This multi-omics analysis reveals distinct immune responses in immunocompromised patients with SARS-CoV-2, implying critical therapeutic insights.
Key Points
Distinct immune responses were observed in COVID-19 patients, particularly among hematological tumor patients, indicating a need for targeted therapies.
The analysis showed significant dysregulation of genes and proteins associated with innate immune responses in immunocompromised individuals.
Network-based drug repositioning highlighted potential therapeutic targets, including HSPA8 and STAT1, for managing COVID-19 complications.
Clinical findings indicated that long COVID patients faced more severe immunosuppression and coagulation issues compared to non-tumor patients.